I am extremely proud to be part of this fantastic new team and excited about the opportunity to form a new value demonstration company in the market access, health economics and outcomes research, patient preference, and real world evidence space that will transform the way medical advances reach the patients who need them. Our new company will support biopharmaceutical clients with the strategy, evidence and communication tools to help maximize the value of their products, guiding healthcare stakeholders worldwide in difficult decisions about resource allocation and access to new therapies.

President and CEO of Evidera, a portfolio company of Symphony Technology Group. Evidera is a global leader in health economics, outcomes research, market access, pricing, epidemiology and data analytics.

Senior Vice President of Strategy, Business Development and Comparative Effectiveness

Leader in BCG's west coast healthcare practice with particular expertise in sales, marketing, corporate and franchise strategy and M&A. Representative projects include:* Product strategy - Developed competitor strategy for $1BN+ injectable biologic facing new competitor entrants * Biotech corporate / TA strategy - Developed strategy for high growth biotech company. Optimized portfolio and suggested M&A strategy for next 5 yrs.* Medical device M&A / partnership strategy - Identified and evaluated inorganic growth options for high growth medical device franchise.

Analyzed business challenges and formulated recommendations to help clients make important strategic, organizational and operational enhancements. Fortune 100 Biotech Company – Managed team of consultants to help coordinate clinical, regulatory, manufacturing, and marketing functions for the launch of a new drug. Fortune 100 Pharma Company - Led team to develop launch strategy for a blockbuster hypercholesterolemia drug into US market and then into EU market.Fortune 100 Pharma Company - Led team of consultants as part of a broader project to make configuration improvements to R&D process. Focus of work included organizational redesign, recognizing and eliminating bottle necks and improving communication of best practices across the organization.Fortune 100 Financial Services Company - Worked for 1-½ years with CEO and SVPs to determine growth strategy and evaluate M&A deals. Evaluated and performed due diligence for numerous acquisition candidates.